Scholarlink

Aim <p>To determine the feasibility and efficacy of <sup>125</sup>Iodine brachytherapy stent (IBS) for lung cancer associated with superior vena cava syndrome (SVCS).</p> Methods <p>From May 2018 to August 2022, a retrospective analysis of 76 patients diagnosed with SVCS who underwent SVC stenting in our department. The ISB group (<i>n =</i> 33) underwent self-expandable metallic stent (SEMS) combined with <sup>125</sup>Iodine seed strand implantation (called ISS), while the conventional stent group (<i>n =</i> 43) underwent SEMS implantation alone. The primary endpoints were technical success, clinical success, complications, stent patency, Karnofsky score; secondary endpoints were progression free survival (PFS) and overall survival (OS).</p> Results <p>There was a significant difference in the stent patency (93.93% vs. 76.74% at 4&#xa0;months) and Karnofsky scores [(81.52 ± 7.95) vs. (77.44 ± 7.90) at 1&#xa0;month, all <i>P &lt;</i> 0.05] between the ISB and conventional stent groups (<i>P &lt;</i> 0.05). No statistically significant differences were observed between two groups in technical success (100% vs. 100%), clinical success (96.97% vs. 93.02%), complication rates (24.24% vs. 11.63%), median PFS (3.40 vs. 3.80&#xa0;months), or median OS (20.40 vs. 20.40&#xa0;months) (<i>P</i> &gt; 0.05).</p> Conclusion <p>The ISB can effectively relieve SVCS, improve functional status, and prolong stent patency, while showing no significance on PFS and OS.</p> Trial registry <p>Ethics Committee of Scientific Research and Clinical Trial, The First Affiliated Hospital of Zhengzhou University.</p> <p>Unique identifying number: Ethics Approval Number: 2023ky0106.</p> <p>Date of registration: 2023.01.12.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

125Iodine brachytherapy stents for lung cancer with superior vena cava syndrome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月4日

查看全文
  • Yipu Li,
  • Zhanguo Sun,
  • Haotian Duan,
  • Mengyao Song,
  • Rongna Hou,
  • Xinwei Han,
  • Yan Yan,
  • Dechao Jiao

摘要

Aim

To determine the feasibility and efficacy of 125Iodine brachytherapy stent (IBS) for lung cancer associated with superior vena cava syndrome (SVCS).

Methods

From May 2018 to August 2022, a retrospective analysis of 76 patients diagnosed with SVCS who underwent SVC stenting in our department. The ISB group (n = 33) underwent self-expandable metallic stent (SEMS) combined with 125Iodine seed strand implantation (called ISS), while the conventional stent group (n = 43) underwent SEMS implantation alone. The primary endpoints were technical success, clinical success, complications, stent patency, Karnofsky score; secondary endpoints were progression free survival (PFS) and overall survival (OS).

Results

There was a significant difference in the stent patency (93.93% vs. 76.74% at 4 months) and Karnofsky scores [(81.52 ± 7.95) vs. (77.44 ± 7.90) at 1 month, all P < 0.05] between the ISB and conventional stent groups (P < 0.05). No statistically significant differences were observed between two groups in technical success (100% vs. 100%), clinical success (96.97% vs. 93.02%), complication rates (24.24% vs. 11.63%), median PFS (3.40 vs. 3.80 months), or median OS (20.40 vs. 20.40 months) (P > 0.05).

Conclusion

The ISB can effectively relieve SVCS, improve functional status, and prolong stent patency, while showing no significance on PFS and OS.

Trial registry

Ethics Committee of Scientific Research and Clinical Trial, The First Affiliated Hospital of Zhengzhou University.

Unique identifying number: Ethics Approval Number: 2023ky0106.

Date of registration: 2023.01.12.